2024 Korean Society of Myocardial Infarction/National Evidence-Based Healthcare Collaborating Agency Guideline for the Pharmacotherapy of Acute Coronary Syndromes
- Author:
Hyun Kuk KIM
1
;
Seungeun RYOO
;
Seung Hun LEE
;
Doyeon HWANG
;
Ki Hong CHOI
;
Jungeun PARK
;
Hyeon-Jeong LEE
;
Chang-Hwan YOON
;
Jang Hoon LEE
;
Joo-Yong HAHN
;
Young Joon HONG
;
Jin Yong HWANG
;
Myung Ho JEONG
;
Dong Ah PARK
;
Chang-Wook NAM
;
Weon KIM
Author Information
- Publication Type:Clinical Practice Guideline
- From:Korean Circulation Journal 2024;54(12):767-793
- CountryRepublic of Korea
- Language:English
- Abstract: Many countries have published clinical practice guidelines for appropriate clinical decisions, optimal treatment, and improved clinical outcomes in patients with acute coronary syndrome. Developing guidelines that are specifically tailored to the Korean environment is crucial, considering the treatment system, available medications and medical devices, racial differences, and level of language communication. In 2017, the Korean Society of Myocardial Infarction established a guideline development committee. However, at that time, it was not feasible to develop guidelines, owing to the lack of knowledge and experience in guideline development and the absence of methodology experts. In 2022, the National EvidenceBased Healthcare Collaborating Agency collaborated with a relevant academic association to develop internationally reliable guidelines, with strict adherence to the methodology for evidence-based guideline development. The first Korean acute coronary syndrome guideline starts from the 9 key questions for pharmacotherapy.
